Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BeiGene, Ltd.
  6. Summary
    BGNE   US07725L1026

BEIGENE, LTD.

(BGNE)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
360.81(c) 376(c) 372.6(c) 375.28(c) 378.88(c) Last
121 063 183 387 107 385 74 540 92 457 Volume
+0.66% +4.21% -0.90% +0.72% +0.96% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 1 246 M - -
Net income 2021 -1 167 M - -
Net cash position 2021 3 810 M - -
P/E ratio 2021 -32,9x
Yield 2021 -
Sales 2022 1 396 M - -
Net income 2022 -1 175 M - -
Net cash position 2022 2 371 M - -
P/E ratio 2022 -29,2x
Yield 2022 -
Capitalization 35 360 M 35 360 M -
EV / Sales 2021 25,3x
EV / Sales 2022 23,6x
Nbr of Employees 6 400
Free-Float 68,2%
More Financials
Company
BeiGene, Ltd. is principally engaged in biopharmaceutical business. The Company is mainly engaged in the research and development, production and sales of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company's main products include Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and Pamiparib (BGB-290). 
More about the company
Ratings of BeiGene, Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about BEIGENE, LTD.
10/21INSIDER SELL : Beigene
MT
10/21BEIGENE : and Nanolek Announce Approval in Russia for BRUKINSA® (Zanubrutinib) for Treatme..
PU
10/21BEIGENE, LTD. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ..
AQ
10/21BEIGENE : Russia Approves BeiGene's Cancer Medicine for Treatment of Mantle Cell Lymphoma
MT
10/20BEIGENE : Brukinsa Gets Russian Approval to Treat Certain Patients With Mantle Cell Lympho..
MT
10/20BEIGENE : and Nanolek Announce Approval in Russia for BRUKINSA® (Zanubrutinib) for Treatme..
BU
10/20Beigene and Nanolek Announce Approval in Russia for Brukinsa? (Zanubrutinib) for Treatm..
CI
10/14BEIGENE : SVB Leerink Adjusts Price Target on BeiGene to $414 From $417, Maintains Outperf..
MT
10/14BeiGene, Ltd. Provides Contract Update with Celgene Logistics Sàrl
CI
10/13BEIGENE : Announces First Regulatory Approval in Australia for BRUKINSA® (Zanubrutinib) fo..
PU
10/13BEIGENE, LTD. : Termination of a Material Definitive Agreement, Other Events, Financial St..
AQ
10/12BEIGENE : Bernstein Starts BeiGene at Outperform With $431 Price Target
MT
10/11BEIGENE : Brukinsa Approved in Australia for Mantle Cell Lymphoma
MT
10/10BeiGene Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mant..
CI
10/10BEIGENE : Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mantl..
BU
More news
News in other languages on BEIGENE, LTD.
10/21VENTE PAR UN INITIÉ : Beigene
10/21La Russie approuve le médicament anticancéreux de BeiGene pour le traitement du lymphom..
10/11Le Brukinsa de BeiGene approuvé en Australie pour le lymphome à cellules du manteau
10/08Le médicament de Beigene contre la macroglobulinémie de Waldenstrom reçoit le feu vert ..
09/24Leap Therapeutics lève 104 millions de dollars après avoir réalisé une offre de titres ..
More news
Analyst Recommendations on BEIGENE, LTD.
More recommendations
Chart BEIGENE, LTD.
Duration : Period :
BeiGene, Ltd. Technical Analysis Chart | BGNE | US07725L1026 | MarketScreener
Technical analysis trends BEIGENE, LTD.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 378,88 $
Average target price 433,96 $
Spread / Average Target 14,5%
EPS Revisions
Managers and Directors
John V. Oyler Chairman & Chief Executive Officer
Xiao Bin Wu President & Chief Operating Officer
Julia Wang Chief Financial & Accounting Officer
Jane E. Huang Chief Medical Officer-Hematology
Yong Ben Chief Medical Officer-Immuno & Oncology Department
Sector and Competitors
1st jan.Capi. (M$)
BEIGENE, LTD.46.63%35 360
GILEAD SCIENCES, INC.15.41%84 306
BIONTECH SE241.44%67 225
WUXI APPTEC CO., LTD.24.51%64 578
REGENERON PHARMACEUTICALS18.47%59 507
VERTEX PHARMACEUTICALS-22.35%47 610